KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other financing activities (2017 - 2025)

Aquestive Therapeutics has reported Other financing activities over the past 7 years, most recently at $7000.0 for Q3 2025.

  • For Q3 2025, Other financing activities fell 12.5% year-over-year to $7000.0; the TTM value through Sep 2025 reached $3000.0, up 100.04%, while the annual FY2023 figure was $4.6 million, N/A changed from the prior year.
  • Other financing activities for Q3 2025 was $7000.0 at Aquestive Therapeutics, down from $8000.0 in the prior quarter.
  • Over five years, Other financing activities peaked at $9.1 million in Q1 2023 and troughed at -$7.9 million in Q4 2023.
  • A 3-year average of $424000.0 and a median of $6000.0 in 2025 define the central range for Other financing activities.
  • On a YoY basis, Other financing activities climbed as much as 99.77% in 2024 and fell as far as 99.94% in 2024.
  • Year by year, Other financing activities stood at -$7.9 million in 2023, then surged by 99.77% to -$18000.0 in 2024, then soared by 138.89% to $7000.0 in 2025.
  • Business Quant data shows Other financing activities for AQST at $7000.0 in Q3 2025, $8000.0 in Q2 2025, and $6000.0 in Q1 2025.